Comparative Pharmacology
Head-to-head clinical analysis: NARCAN versus ZIMHI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NARCAN versus ZIMHI.
NARCAN vs ZIMHI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Opioid receptor antagonist; binds competitively to mu, kappa, and delta opioid receptors, reversing opioid effects.
Opioid receptor antagonist; reverses opioid effects by competitively binding to mu-opioid receptors.
Initial dose: 0.4 mg to 2 mg IV, IM, or SC, repeated every 2 to 3 minutes as needed. For opioid-induced respiratory depression, may use 0.1 to 0.2 mg IV increments in patients with opioid dependence to avoid withdrawal.
5 mg intramuscularly every 2-3 minutes as needed; maximum 3 doses.
None Documented
None Documented
Approximately 1 hour in adults; context: shorter than most opioids (e.g., morphine 2-4 h), necessitating repeated doses for prolonged opioid effects.
Terminal half-life: 2.5-4 hours; clinical context: short duration requires repeat dosing for sustained opioid effects.
Primarily hepatic metabolism (glucuronidation) followed by renal excretion of metabolites; <5% excreted unchanged in urine.
Renal: 30-35% unchanged; biliary/fecal: 50-60% as metabolites.
Category C
Category C
Opioid Antagonist
Opioid Antagonist